Pfizer To Undercut J&J With New Remicade Biosimilar
Pfizer will sell its version of the drug at a 15 percent discount of Johnson & Johnson's blockbuster rheumatoid-arthritis treatment.
The Associated Press:
Pfizer To Launch Cheaper Version Of J&J Immune Drug Remicade
Drugmaker Pfizer said Monday that it will launch a less-expensive version of rival Johnson & Johnson’s blockbuster immune disorder drug, Remicade. Pfizer Inc.’s version, called Inflectra, will hit pharmacies in late November. It will be only the second so-called biosimilar drug available in the U.S. (Johnson, 10/17)
The Wall Street Journal:
Pfizer Plans To Launch Remicade Biosimilar In November
The announcement is likely to set up a fierce battle, in the courts as well as in contract talks with health insurers, between two of the biggest drug companies in the world by sales. Pfizer is launching its version, called Inflectra, before the resolution of an ongoing patent dispute with Remicade’s maker Johnson & Johnson. (Rockoff, 10/17)